Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
NEW YORK and SEOUL, South Korea, Jan. 23, 2026 (GLOBE NEWSWIRE) -- K Wave Media (the “Company”) announced today that it received a written notification (the “Notice”) from the Nasdaq Stock Market...
-
MALVERN, Pa., Jan. 23, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction...
-
VANCOUVER, British Columbia, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Equity Insider News Commentary — Global institutions forecast mineral prices to trend higher in 2026 as net-zero demand and critical...
-
trivago N.V.'s Fourth Quarter 2025 Earnings Release Scheduled for February 3, 2026; Webcast Scheduled for February 4, 2026 DÜSSELDORF, GERMANY – January 22, 2026 - trivago N.V. (NASDAQ: TRVG)...
-
VANCOUVER, British Columbia, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Maxus Mining Inc. (“Maxus” or the “Company”) (CSE: MAXM | FRA: R7V), is pleased to announce investors have exercised 2,408,200 common...
-
Washington, D.C., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Pending home sales in December decreased by 9.3% from the prior month and 3.0% year over year, according to the National Association of REALTORS®...
-
RA'ANANA, Israel, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN,IINNW) ("Inspira" or the "Company"), a pioneer in innovative life-support and diagnostic...
-
Final EB613 Phase 3 Protocol Submission to FDA Planned for Q1 2026, Following December 19th 2025 FDA Ruling Next-Generation EB613 Phase 1 Bridging Study Progressing with Results Expected During Q1...
-
Grand Cayman, Cayman Island, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (“Silexion” or the “Company”), a clinical-stage, oncology-focused biotechnology company, today announced...
-
Interim results indicate NS002 demonstrated significantly faster absorption and higher peak epinephrine levels compared to EpiPen® 91% of study participants achieved the 100 pg/ml plasma threshold...